Isryl-M1Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. This dual-action formulation offers complementary mechanisms to achieve better glycemic control in patients inadequately controlled by diet, exercise, and monotherapy. Isryl-M1Forte Tablet PR is typically prescribed when monotherapy with either agent is insufficient, providing effective control of fasting and postprandial blood glucose. The extended-release formulation ensures sustained plasma drug levels, improving patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. It is essential to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with Metformin, especially in patients with renal impairment or other contraindications. Dose adjustments may be necessary based on glycemic response and tolerability. Isryl-M1Forte Tablet PR should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose and HbA1c levels.